Project
Arimoclomol in Amyotropic Lateral Sclerosis
Aborted ยท 2018 until 2020
Neuwirth Christoph
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Aborted
Start Date
2018
End Date
2020
Financing
Industry
Brief description/objective
A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)